Klempner, S., Strickler, J., Gourley, L., Jacquemont, C., Bhatia, V., Hunder, N., … Piha-Paul, S. (2021). 393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A426–A426). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.393

Klempner, Samuel, John Strickler, Lindsey Gourley, Celine Jacquemont, Vinona Bhatia, Naomi Hunder, Valerie Odegard, and Sarina Piha-Paul. “393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers.” In Journal for ImmunoTherapy of Cancer, 9:A426–A426. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.393.

Klempner S, Strickler J, Gourley L, Jacquemont C, Bhatia V, Hunder N, et al. 393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers. In: Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A426–A426.

Klempner, Samuel, et al. “393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A426–A426. Crossref, doi:10.1136/jitc-2021-sitc2021.393.

Klempner S, Strickler J, Gourley L, Jacquemont C, Bhatia V, Hunder N, Odegard V, Piha-Paul S. 393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers. Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A426–A426.